NVS

ACCE-researched
Novartis AG Common Stock
Healthcare · Drug Manufacturers - General · NYSE · United States
$140.98+0.43%
Market cap $266.8BNext earnings 2026-10-27Updated Sep 20, 2026
FAIR VALUE · CONSENSUS
$140.98+0.0%
confidence-weighted across 5 of 6 models
Now $140.98
$140.98
$62.66$206.72
HoldBronze40
Price vs fair value
5.3% above
-5.0% to fair value
ACCE score
58
out of 100
Analysts
15% buy
13 covering
P/E
21.2x
forward 14.5x
1-year return
+14.7%
Dividend yield
3.38%
Unlock the ACCE read
INVESTOR

Overview

⚠ Investor warnings · 2 flags
  • moderate
    Earnings decline accelerating
    Earnings YoY -9.3% with revenue also down -0.7% and QoQ -2.4%, suggesting near-term fundamental deterioration beyond a one-off.
  • moderate
    Low growth ACCE score
    Growth sub-score of 7/100 is extremely weak, consistent with negative revenue and earnings trends across multiple timeframes.
Reports in 35 days, last quarter beat by 0.1%.

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Price

+14.3% · 1Y

Valuation

INVESTOR
Full valuation engine INVESTOR FEATURE

Six independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.

  • +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
  • +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
  • +Editable DCF workbench with saved scenarios

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.

  • +Conviction score breakdown and earnings-quality grade
  • +Growth / value / quality / momentum component scores
  • +90-day score history and score-threshold backtests

Analysts

Wall Street consensus

Bearish15% buy · 13 covering analysts
● Strong buy 0● Buy 2● Hold 9● Sell 0● Strong sell 2
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO
Smart money tracking PRO FEATURE

Follow the institutions: 13F position changes, insider trades, and active 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Recent open-market insider transactions
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

This stock Peer Peer median weaker → stronger
P/Ebetter than 83% of peers
low 10.7x21.2xhigh 117.5x
ROEbetter than 67% of peers
low 7%30%high 91%
Div yieldbetter than 67% of peers
low 1.9%3.4%high 4.2%

Algorithmic peers (6)

TickerCompanyMcapP/EROED/EYieldQuality
NOVN.SWNovartis$268.7B21.230.3%0.734.0%-Compare
AZN.LAstraZeneca$260.9B25.122.0%0.572.6%-Compare
AZNAstraZeneca PLC Ordinary Shares$257.6B24.922.0%0.571.9%-Compare
AMGNAmgen Inc. Common Stock$208.5B24.091.5%6.312.6%-Compare
MRKMerck & Company Inc. Common Stock (new)$362.4B117.57.0%0.942.3%-Compare
NOVO-B.CONovo Nordisk B$191.2B10.759.8%0.634.2%-Compare

Sector report card

Where NVS ranks against its sector peers on each metric.

Computing percentiles…

News and Record

Reports in 35 days, last quarter beat by 0.1%.

Press releases mentioning this company

Ask anything, Pro feature

Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.

PRO

Recent performance

1 week
+1.4%
1 month
-11.3%
3 months
-8.1%
6 months
-6.5%
YTD
+2.3%
1 year
+14.7%

SEC filings

16 filings of 35
September 2026
Sep 8
6-KForeign current reportPeriod 2026-09-08
Sep 4
6-KForeign current reportPeriod 2026-09-04
Sep 1
6-KForeign current reportPeriod 2026-09-01
13 more filings + AI summaries on Investor+.INVESTOR